ONO PHARMA, Apr-Jun (1Q) Net Income Decreases by 29%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Aug 1, 2025 12:00 pm JST Earnings

4528 ONO PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

ONO PHARMACEUTICAL CO., LTD. <4528> [TSE Prime] announced its financial results (based on IFRS) at noon (12:00) on August 1st. The consolidated net income for the first quarter of the fiscal year ending March 2026 (April to June) decreased 28.7% from the same period last year to 17.6 billion yen. Progress toward the full-year plan of 67.0 billion yen was 26.4%, below the five-year average of 31.8%.

In the most recent three-month period, from April to June (1Q), the operating profit margin significantly dropped from 26.1% in the same period last year to 17.2%.

Kabutan News

Actual Results

Accumulated Results 1st Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Jun, 2023	120,016	41,348	42,378	31,818	65.2	42.7	Jul 31, 2023	IFRS
Apr - Jun, 2024	117,675	30,690	33,310	24,794	52.8	70.1	Jul 31, 2024	IFRS
Apr - Jun, 2025	127,536	21,995	22,650	17,673	37.6	ー	Aug 1, 2025	IFRS
YoY	+8.4%	-28.3%	-32.0%	-28.7%	-28.7%

Current Period Guidance

H1 Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024	240,339	48,788	47,544	37,435	79.7	40	Oct 31, 2024	IFRS
Apr - Sep, 2025 Guidance	ー	ー	ー	ー	－	40	May 8, 2025	IFRS
YoY	－	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2024	502,672	159,935	163,734	127,977	266.6	80	May 9, 2024	IFRS
Mar, 2025	486,871	59,747	59,328	50,047	106.6	80	May 8, 2025	IFRS
Mar, 2026 Guidance	490,000	85,000	85,000	67,000	142.6	80	May 8, 2025	IFRS
YoY	+0.6%	+42.3%	+43.3%	+33.9%	+33.8%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Apr - Jun, 2024	117,675	30,690	33,310	24,794	52.8	26.1	Jul 31, 2024	IFRS
Jul - Sep, 2024	122,664	18,098	14,234	12,641	26.9	14.8	Oct 31, 2024	IFRS
Oct - Dec, 2024	134,223	21,966	24,493	19,157	40.8	16.4	Feb 3, 2025	IFRS
Jan - Mar, 2025	112,309	-11,007	-12,709	-6,545	-13.9	-9.8	May 8, 2025	IFRS
Apr - Jun, 2025	127,536	21,995	22,650	17,673	37.6	17.2	Aug 1, 2025	IFRS
YoY	+8.4%	-28.3%	-32.0%	-28.7%	-28.7%